• We are a biotech company in
    infectious diseases with a
    first marketed product.

  • We are dedicated to
    innovation in antibody
    discovery and vaccine R&D.

  • Valneva covers the full
    value chain from bench
    to market.

Welcome to Valneva

Joining forces to create a European biotech leader in vaccines and antibodies


— September 19, 2014

Valneva welcomes the Texas A&M inauguration of EB66®-Based influenza vaccine facility in Texas, on track for 2016 start-up Phase
Download PR

— Stock information



—News, May 19, 2014

Valneva Announces the First Ever Marketing Approval in Europe for a vaccine produced in the EB66® Cell Line

 All News

— Financial calendar

 All dates

November 6, 2014
Q3 Results 


- August 8, 2014
Valneva reported its first half results - Significant reduction in net loss and EBITDA
Download PR
Download Half Year Report
Download Analysts Presentation
View Webcast

— Upcoming conferences and fairs

November 3 - 5, 2014
Frankfurt, Germany

December 3 - 4, 2014
VIC Congress
Brussels, Belgium

March 9 - 11, 2015
BioEurope Spring
Paris, France

June 15 - 18, 2015
Bio International Convention
Philadelphia, United States

Meet our Business Development team


European biotech company with worldwide presence.

Please update your browser...